Virtu KCG Holdings’s Theriva Biologics TOVX Stock Holding History

Virtu KCG Holdings’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$34K	Sell	7 -3	-30%	-$14.9K	﹤0.01%	2662
2017 Q1	$54K	Sell	10 -10	-50%	-$69.8K	﹤0.01%	2829
2016 Q4	$133K	Buy	20 +17	+567%	+$175K	﹤0.01%	2801
2016 Q3	$50K	Sell	3 -4	-57%	-$59.9K	﹤0.01%	2783
2016 Q2	$106K	Buy	+7	New	+$132K	﹤0.01%	2523
2016 Q1	–	Sell	-18	Closed	-$362K	–	3642
2015 Q4	$362K	Buy	18 +13	+260%	+$275K	0.01%	1924
2015 Q3	$107K	Buy	5 +4	+400%	+$98.4K	﹤0.01%	2813
2015 Q2	$34K	Sell	1 -8	-89%	-$161K	﹤0.01%	3130
2015 Q1	$176K	Hold	9	–	–	﹤0.01%	2461
2014 Q4	$119K	Buy	9 +4	+80%	+$53.7K	﹤0.01%	3148
2014 Q3	$74K	Buy	+5	New	+$81.3K	﹤0.01%	3256

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Virtu KCG Holdings's TOVX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Theriva Biologics (TOVX) stake by 30% in Q2 2017, selling an estimated $14.9K and leaving 7 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #2662.

Virtu KCG Holdings first reported a position in TOVX in Q3 2014 and has held it in 11 quarters since. The position peaked at $362K in Q4 2015. 53 funds tracked by Wall St. Rank hold TOVX as of Q2 2017.

Virtu KCG Holdings held 7 shares of Theriva Biologics worth $34K as of Q2 2017.
Virtu KCG Holdings sold 3 Theriva Biologics shares in Q2 2017, an estimated $14.9K.
Theriva Biologics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2662 holding.
Virtu KCG Holdings first reported a position in Theriva Biologics in Q3 2014 and has held it in 11 quarters since.
Virtu KCG Holdings's Theriva Biologics position peaked at $362K in Q4 2015.
53 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.